Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial
Beteiligte Einrichtungen
Abstract
BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.
OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).
METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.
RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.
CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 1018-8665 |
DOIs | |
Status | Veröffentlicht - 01.01.2013 |
PubMed | 24281309 |
---|